Faculty

Perry B. Molinoff, M.D.

faculty photo
Emeritus Professor of Pharmacology
Department: Systems Pharmacology and Translational Therapeutics

Contact information
Department of Pharmacology
204 Anatomy-Chemistry Building
Philadelphia, PA 19104
Office: (215) 898-2832
Fax: (215) 898-2718
Education:
B.S.
Harvard College, Boston, MA, 1962.
M.D.
Harvard University, Boston, MA, 1967.
Permanent link
 
> Perelman School of Medicine   > Faculty   > Details

Description of Research Expertise

Dr. Molinoff is an expert on the structure and function of cell membrane receptors involved in signal transduction. His early research focused on the receptor for the neurotransmitter acetylcholine, but he has published extensively on other important receptor molecules that respond to amino acids or to biogenic amines such as dopamine. Much of this research has had significant clinical relevance for understanding and treating diseases ranging from heart failure to depression, schizophrenia and Parkinson's disease.

Selected Publications

Rosen RC, Diamond LE, Earle DC, Shadiack AM, Molinoff PB: Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra. Intl J Impotence Res 16: 135-142, 2004.

Diamond LE, Earle DC, Rosen RC, Willett MS, Molinoff PB: Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction. Intl J Impotence Res 16: 51-59, 2004.

Molinoff PB, Shadiack AM, Earle D, Diamond LE, Quon CY: PT-141: A melanocortin agonist for the treatment of sexual dysfunction. Ann New York Acad Sci 994: 96-102, 2003.

Nakai S, Hirose T, Uwahodo Y, Imaoka T, Okazaki H, Miwa T, Nakai M, Yamada S, Dunn B, Burris KD, Molinoff PB, Tottori K, Altar CA, Kikuchi T: Diminished catalepsy and dopamine metabolism distinguish aripiprazole from haloperidol or risperidone. Eur J Pharmacol 472: 89-97, 2003.

Burris KD, Molski TF, Xu C, Ryan E, Tottori K, Kikuchi T, Yocca FD, Molinoff PB: Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 302: 381-389, 2002.

Molinoff PB: Common to both academia and industry: The challenge of discovery. An interview with Perry Molinoff. Mol Intervent 1: 78-83, 2001.

Gribkoff VK, Starrett JE Jr, Dworetzky SI, Hewawasam P, Boissard CG, Cook DA, Frantz SW, Heman K, Hibbard JR, Huston K, Johnson G, Krishnan BS, Kinney GG, Lombardo LA, Meanwell NA, Molinoff PB, Myers RA, Moon SL, Ortiz A, Pajor L, Pieschl RL., Post-Munson DJ, Signor LJ, Srinivas N, Taber MT, Thalody G, Trojnacki JT, Wiener H, Yeleswaram K, Yeola SW: Targeting acute ischemic stroke with a calcium-sensitive opener of maxi-K potassium channels. Nature Med 7: 471-477, 2001.

Wohlpart KL and Molinoff PB: Characterization of 5-HT- and ionomycin-stimulated changes in levels of intracellular calcium and PI hydrolysis in P11 cells. Ann New York Acad Sci 861: 240-241, 1998.

Burris KD, Fausing SM, Molinoff PB: Regulation of D2 and D3 receptors in transfected cells by agonists and antagonists. Adv Pharmacol 42: 443-446, 1998.

Cowen DS, Molinoff PB, Manning DR: 5-hydroxytryptamine1A receptor-mediated increases in receptor expression and activation of nuclear factor-kappaB in transfected Chinese hamster ovary cells. Mol Pharmacol 52: 221-226, 1997.

back to top
Last updated: 04/02/2013
The Trustees of the University of Pennsylvania